|
! Handelsnaam !! Geneesmiddelnaam !! Goedgekeur deur FDA in VSA !! Maatskappy
|-
| "Combivir" || [[sidovudienSidovudien]] + [[lamivudien]] || 26 September 1997 || GlaxoSmithKline
|-
| "Trizivir" || [[abakavirAbakavir]] + [[sidovudien]] + [[lamivudien]] || 15 November 2000 || GlaxoSmithKline
|-
| "Aluvia" tablette<br />"Kaletra" orale oplossing|| [[lopinavirLopinavir/ritonavir|lopinavir + ritonavir]] || 15 September 2000 || Abbott Laboratories
|-
| "Epzicom" (in VSA)<br />"Kivexa" (in Europa) || abakavirAbakavir + [[lamivudien]] || 2 Augustus 2004 || GlaxoSmithKline
|-
| "Truvada" || [[tenofovirTenofovir]]/[[emtrisitabien]] || 2 Augustus 2004 || Gilead Sciences
|-
| "Atripla" <br /> "Odimune"|| [[Emtrisitabien/tenofovir/efavirens]] || 12 Julie 2006 || Gilead Sciences/Bristol-Myers Squibb <br /> Cipla
|-
| "Complera" || rilpivirienRilpivirien + [[tenofovir]]/[[emtrisitabien]] || 10 Augustus 2011 || Gilead Sciences en <br />Tibotec (Johnson & Johnson)
|-
| "Stribild" || elvitegravirElvitegravir + cobicistat + [[tenofovir]]/[[emtrisitabien]] || 27 Augustus 2012 || Gilead Sciences
|}
In Augustus 2012 is die verkose eerste-linie terapie in die [[VSA]]:
* [[tenofovirTenofovir]]/[[emtrisitabien]] ('n kombinasie van twee [[nukleosied analoog trutranskriptase remmer|NRTIs]]) en [[efavirens]] ('n [[nie-nukleosied trutranskriptase remmer|NNRTI]]).
* tenofovirTenofovir/emtrisitabien en raltegravir
* tenofovirTenofovir/emtrisitabien, [[ritonavir]], en darunavir (die laaste twee is protease-ensiemremmers)
* tenofovirTenofovir/emtrisitabien, ritonavir, en [[atazanavir]] (die laaste twee is protease-ensiemremmers).
{{Commonskat|Antiretroviral drugs}}
| 